CVS HEALTH Corp（CVS）の決算・業績分析
CVS HEALTH Corpの2025年有価証券報告書をAI分析。売上高$402.1B(+7.8%)。営業利益$4.7B。Consumer Staples。
目次
CVS HEALTH Corpの2025年度 業績サマリー
CVS HEALTH Corp（証券コード: CVS）の2025年度決算・業績分析。売上高は$402.1B（前年比+7.8%）。営業利益は$4.7B（前年比-45.3%）。純利益は$1.8B（前年比-61.7%）。有価証券報告書を基に、業績変化の要因・リスク・見通し・セグメント構成を AI が分析しました。
CVS HEALTH Corpの2024年度 注目ポイント
※ 直近の2025年度XBRLデータは取込済みですが、AI分析は2024年度の10-Kを対象としています。
- Revenue increased by 10.4% YoY to $322.5B (XBRL), but operating income fell by 40.2% YoY to $8.0B (XBRL).
- Free cash flow reached $13.4B (XBRL), driven by $16.2B operating cash flow (XBRL) and $2.7B CapEx (XBRL).
- Net income declined by 46.1% YoY to $4.3B (XBRL), with net margin dropping to 1.3% (XBRL).
- Debt-to-equity ratio rose to 2.26x (XBRL), while current ratio fell to 0.86x (XBRL), signaling liquidity concerns.
- 5-year revenue CAGR of 13.0% (XBRL) contrasts with sharp declines in operating income and net income in FY2024.
CVS HEALTH Corpの売上高変化の要因
- •Revenue grew to $322.5B (XBRL), up 10.4% YoY, with a 5-year CAGR of 13.0% (XBRL). However, operating income fell by 40.2% YoY to $8.0B (XBRL), reflecting a sharp decline from $13.3B in FY2023 (XBRL). Segment-specific revenue or product breakdowns are not disclosed in the provided data (XBRL). Growth drivers include expanded retail pharmacy services and health insurance offerings, though operating income trends suggest cost pressures or margin compression.
CVS HEALTH Corpの営業利益変化の要因
- •Operating margin declined to 2.5% (XBRL), down from FY2023’s 4.6% (calculated from $13.3B operating income / $292.1B revenue). Net margin fell to 1.3% (XBRL), down from 2.7% in FY2023 (calculated from $8.0B net income / $292.1B revenue). EBITDA of $12.2B (XBRL) represents a 3.8% margin (calculated from $12.2B / $322.5B). Operating income dropped by $5.3B YoY (from $13.3B in FY2023 to $8.0B in FY2024) (XBRL).
CVS HEALTH Corpの事業リスクと対応
Inability to forecast healthcare costs accurately (10-K).
Adverse economic conditions impacting financial performance (10-K).
Highly competitive business environment across segments (10-K).
Changes in product mix affecting profit margins (10-K).
Risks related to solvency of other insurers (10-K).
Regulatory and legal risks, including compliance failures and audits in PBM, Medicare/Medicaid, and Public Exchange businesses (10-K).
CVS HEALTH Corpの今後の見通し・業績予想
CVS HEALTH Corpの事業内容
CVS Health operates as a health solutions company, generating revenue through health insurance products, pharmacy benefits management, and health services (10-K). Key segments include Health Care Benefits (insurance), Health Services (clinics), Pharmacy & Consumer Wellness (retail pharmacies), and Corporate/Other (10-K). Competitive advantages include an integrated care model, technology-driven services, and scale (9,000 retail locations, 1,000 clinics) (10-K). No significant customer concentration is reported (10-K).
CVS HEALTH CorpのAI業績分析レポート（2024年度）
CVS Health Corp (CVS) FY2024 Annual Report Analysis
Highlights
Business Overview
CVS Health operates as a health solutions company, generating revenue through health insurance products, pharmacy benefits management, and health services (10-K). Key segments include Health Care Benefits (insurance), Health Services (clinics), Pharmacy & Consumer Wellness (retail pharmacies), and Corporate/Other (10-K). Competitive advantages include an integrated care model, technology-driven services, and scale (9,000 retail locations, 1,000 clinics) (10-K). No significant customer concentration is reported (10-K).
Revenue Analysis
Revenue grew to $322.5B (XBRL), up 10.4% YoY, with a 5-year CAGR of 13.0% (XBRL). However, operating income fell by 40.2% YoY to $8.0B (XBRL), reflecting a sharp decline from $13.3B in FY2023 (XBRL). Segment-specific revenue or product breakdowns are not disclosed in the provided data (XBRL). Growth drivers include expanded retail pharmacy services and health insurance offerings, though operating income trends suggest cost pressures or margin compression.
Profitability Analysis
Operating margin declined to 2.5% (XBRL), down from FY2023’s 4.6% (calculated from $13.3B operating income / $292.1B revenue). Net margin fell to 1.3% (XBRL), down from 2.7% in FY2023 (calculated from $8.0B net income / $292.1B revenue). EBITDA of $12.2B (XBRL) represents a 3.8% margin (calculated from $12.2B / $322.5B). Operating income dropped by $5.3B YoY (from $13.3B in FY2023 to $8.0B in FY2024) (XBRL).
Balance Sheet Analysis
Total assets increased to $249.7B (XBRL), up from $228.3B in FY2023. Equity rose to $76.5B (XBRL), with an equity ratio of 30.6% (XBRL). Debt-to-equity ratio of 2.26x (XBRL) indicates high leverage. Current ratio of 0.86x (XBRL) suggests potential short-term liquidity challenges. Cash reserves stood at $12.9B (XBRL).
Cash Flow Analysis
Operating cash flow totaled $16.2B (XBRL), with free cash flow of $13.4B (XBRL) after $2.7B CapEx (XBRL). Investing cash flow was -$5.0B (XBRL), while financing cash flow was -$10.5B (XBRL), including $2.9B in dividends (XBRL) and $3.5B in share repurchases (XBRL). CapEx intensity of 0.8% (XBRL) and CapEx/D&A ratio of 0.65x (XBRL) reflect conservative capital spending.
Working Capital Analysis
Receivables days: 40 days (XBRL), inventory days: 33 days (XBRL). Asset turnover: 1.29x (XBRL). Payables days and cash conversion cycle (CCC) data are not available (N/A). Current ratio of 0.86x (XBRL) suggests potential working capital constraints.
Risks
Outlook
Management guidance and forward-looking trends are not explicitly detailed in the 10-K. However, historical revenue growth (5-year CAGR of 13.0% (XBRL)) and expansion of retail pharmacy and health services suggest continued focus on scaling operations, despite recent declines in operating income and net income.
Consumer Staplesの企業一覧
CVS HEALTH Corpと同じ「Consumer Staples」セクターの企業